Johnson & Johnson (JNJ) Return on Capital Employed (2009 - 2026)
Johnson & Johnson (JNJ) posted Return on Capital Employed of 17.83% for Q2 2026, down 0.68% sequentially from 17.95% in Q1 2026, and up 242.0% YoY from 5.21% in Q2 2025.
Johnson & Johnson (JNJ) Return on Capital Employed (2009 - 2026) Analysis & Trends
Johnson & Johnson has reported Return on Capital Employed for 18 years, with the latest figure at 17.83% in Q2 2026.
- Quarterly Return on Capital Employed rose 242.0% year-over-year to 17.83% in Q2 2026, while the trailing twelve-month figure through Jun 2026 was 17.83% (up 242.0% YoY) and the FY2025 annual result came in at 18.72%, up 170.0% from the prior year.
- Return on Capital Employed retreated to 17.83% in Q2 2026 per JNJ's latest filing, from 17.95% in the prior quarter.
- Over five years, Return on Capital Employed peaked at 19.98% in Q4 2023 and troughed at 15.38% in Q4 2022.
- A 5-year average of 17.43% and a median of 17.84% in 2023 frame the typical range for Return on Capital Employed.
- The sharpest annual moves came in 2022 and 2023: Return on Capital Employed sank 528 bps in 2022, then soared 460 bps in 2023.
- Over 5 years, Return on Capital Employed stood at 15.38% in 2022, then advanced by 16 bps to 17.85% in 2023, then retreated by 9 bps to 16.31% in 2024, then grew by 10 bps to 17.88% in 2025, then fell by 0 bps to 17.83% in 2026.
- According to Business Quant data, Return on Capital Employed over the past three periods registered 17.83%, 17.95%, and 17.88% for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 17.83% |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 17.92% |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 9.96% |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | - |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | 16.76% |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 16.66% |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | -5.97% |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | 11.86% |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | 11.42% |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn | 79.25% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 28, 2026 | 17.83% |
| Mar 29, 2026 | 17.95% |
| Dec 28, 2025 | 17.88% |
| Sep 28, 2025 | 16.49% |
| Jun 29, 2025 | 15.40% |
| Mar 30, 2025 | 16.38% |
| Dec 29, 2024 | 16.31% |
| Sep 29, 2024 | 16.94% |
| Jun 30, 2024 | 18.25% |
| Mar 31, 2024 | 17.94% |
| Dec 31, 2023 | 17.85% |
| Oct 1, 2023 | 19.98% |
| Jul 2, 2023 | 18.93% |
| Apr 2, 2023 | 18.66% |
| Jan 1, 2023 | 18.44% |
| Oct 2, 2022 | 15.38% |
| Jul 3, 2022 | 15.79% |
| Apr 3, 2022 | 17.37% |
| Oct 3, 2021 | 20.67% |
| Jul 4, 2021 | 19.67% |